Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers Health (HIMS) shares are up 20% this morning after announcing a new partnership with Novo Nordisk (NVO). 

Novo Nordisk expects that teaming up with HIMS will help further expand access to its weight-loss treatment, Wegovy, which it confirmed is no longer facing supply shortages in the U.S. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.